Drug Profile
Diflomotecan
Alternative Names: BN-80915; R1536Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Biomeasure Inc
- Developer Ipsen
- Class Antineoplastics; Camptothecins; Small molecules
- Mechanism of Action Apoptosis stimulants; DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Small cell lung cancer
Most Recent Events
- 29 Dec 2010 Discontinued - Phase-II for Small cell lung cancer in France (PO)
- 29 Dec 2010 Discontinued - Phase-II for Small cell lung cancer in Netherlands (PO)
- 29 Dec 2010 Discontinued - Phase-II for Small cell lung cancer in United Kingdom (PO)